Despite the need for further studies to fully elucidate the aforementioned phenomena, adiponectin signaling in PVAT has clearly emerged as a potential therapeutic target for cardiovascular and metabolic disorders. This evidence concerns the gene ADIPOQ and Other metabolic disease.